Premium
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects
Author(s) -
Cabaleiro Teresa,
LópezRodríguez Rosario,
Ochoa Dolores,
Román Manuel,
Novalbos Jesús,
AbadSantos Francisco
Publication year - 2013
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2308
Subject(s) - olanzapine , pharmacokinetics , pharmacology , pharmacodynamics , pharmacogenetics , medicine , adverse effect , cyp3a5 , genotype , biology , genetics , psychiatry , gene , schizophrenia (object oriented programming)
Objective The pharmacokinetics of olanzapine and response to treatment could be affected by polymorphisms in genes coding for drug‐metabolizing enzymes, transporters, or receptors. The aim of this study was to identify genetic markers predictive of pharmacokinetics, pharmacodynamics, and adverse effects of olanzapine. Methods Sixty‐three healthy volunteers receiving a single 5‐mg oral dose of olanzapine were genotyped for 39 genetic variants that could be related to the response to olanzapine. All genetic variants were analyzed by PharmaChip, but DRD2 Taq1A polymorphism was determined by real‐time polymerase chain reaction. Olanzapine was measured using high‐performance liquid chromatography combined with tandem mass spectrometry. The relationship of gender and polymorphisms with olanzapine pharmacokinetics, the change in prolactin levels, and the incidence of adverse effects were evaluated by multiple regression analysis. Results The pharmacokinetics of olanzapine was influenced by polymorphisms in CYP3A5 , GSTM3 , and GRIN2B . Prolactin levels were affected by gender and polymorphisms in DRD2 and 5‐ HTR2A . Polymorphisms in CYP2C9 , TPMT , UGT1A1 , MDR1 , and 5‐ HTR2A were related to some adverse effects of olanzapine. Conclusions Several polymorphisms can explain differences in the pharmacokinetics, pharmacodynamics, and safety of olanzapine in healthy subjects. Whether these genetic factors influence the risk of therapeutic failure or tolerability in patients remains to be established. Copyright © 2013 John Wiley & Sons, Ltd.